Edition:
United Kingdom

Cumberland Pharmaceuticals Inc (CPIX.OQ)

CPIX.OQ on NASDAQ Stock Exchange Global Select Market

6.75USD
7:09pm GMT
Change (% chg)

$-0.10 (-1.46%)
Prev Close
$6.85
Open
$6.70
Day's High
$6.90
Day's Low
$6.70
Volume
1,774
Avg. Vol
3,909
52-wk High
$7.95
52-wk Low
$5.30

Latest Key Developments (Source: Significant Developments)

Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Cumberland Pharmaceuticals Inc ::Cumberland Pharmaceuticals Inc files for mixed shelf of up to $100 million .  Full Article

Cumberland Pharmaceutical reports Q3 loss per share $0.05
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Cumberland Pharmaceuticals Inc :Cumberland Pharmaceutical reports 27% revenue growth in the third quarter.Q3 adjusted earnings per share $0.01.Q3 revenue rose 27 percent to $11.2 million.Q3 loss per share $0.05.  Full Article

Clinigen and Cumberland Pharmaceuticals launch dry mouth drug in U.S
Monday, 26 Sep 2016 

Clinigen Group Plc :Clinigen GrouE and Cumberland Pharmaceuticals launch Rthyol® in U.S.  Full Article

Cumberland Pharmaceuticals posts Q2 adj. earnings $0.04/shr
Tuesday, 2 Aug 2016 

Cumberland Pharmaceuticals Inc : Q2 adjusted earnings per share $0.04 . Q2 earnings per share $0.00 .Q2 revenue $7.4 million versus $8.9 million.  Full Article

Cumberland Pharmaceuticals Q1 adjusted earnings per share $0.02
Tuesday, 10 May 2016 

Cumberland Pharmaceuticals Inc : Cumberland Pharmaceuticals Inc says as of march 31, 2016, company had just under $90 million in total assets including over $51 million in cash and marketable securities . Cumberland Pharmaceuticals reports first quarter 2016 financial results . Q1 adjusted earnings per share $0.02 .Q1 revenue $7.7 million versus $8.7 million.  Full Article

Clinigen, Cumberland enter into U.S. commercialisation deal for ethyol
Tuesday, 10 May 2016 

Clinigen Group Plc :Co and Cumberland Pharmaceuticals enter into exclusive u.s. Commercialisation agreement for oncology support drug ethyol.  Full Article

BRIEF-Cumberland Pharma Says Data Demonstrates Amifostine Reduces Gastro-Intestinal Toxicity For Multiple Myeloma Patients

* CUMBERLAND PHARMACEUTICALS INC - NEWLY PUBLISHED DATA DEMONSTRATES AMIFOSTINE REDUCES GASTRO-INTESTINAL TOXICITY FOR MULTIPLE MYELOMA PATIENTS Source text for Eikon: Further company coverage: